whatpeptidestostackFat loss and metabolic
What the published literature pairs among metabolic compounds, graded by evidence. Most are studied alone, and the atlas says so.
Compounds in this area
A mitochondrial-derived peptide studied mainly for metabolism in mice. Human data are observational only, and no complet
RetatrutideA single peptide that activates the GIP, GLP-1 and glucagon receptors. It has the strongest human evidence in this atlas
SLU-PP-332A synthetic exercise mimetic studied in mice for metabolism, heart failure and kidney aging. No human has been given it
TesamorelinA GHRH analogue and the one FDA-approved compound in this atlas, cleared for a specific HIV-related use. Evidence outsid
TirzepatideAn approved dual-incretin medicine with strong human evidence. This atlas covers it for research context only; its affil
Graded pairings
Glutathione and SLU-PP-332
These two appear in one laboratory study, but only because glutathione was measured as a readout while cells were treated with SLU-PP-332.
Open →PT-141 and Tirzepatide
A registered trial has begun giving both compounds to the same subjects. No result has been reported, so the pairing is a registration, not a finding.
Open →Reading this goal in one minute
Five compounds sit here, and only two graded pairings touch them. Neither is a tested combination.
- Glutathione and SLU-PP-332 are co-studied: glutathione was a lab readout, not a second treatment.
- PT-141 and Tirzepatide are co-administered in a registered trial with no reported result.
That's the whole shelf.
The human evidence is uneven:
- Tirzepatide is an approved medicine.
- Retatrutide has the strongest human evidence in the atlas.
- Tesamorelin is approved only for a specific HIV-related use.
- MOTS-c has observational human data.
- SLU-PP-332 has never been given to a human.
Open each compound profile for the cited record, and see the evidence base for how we assign every grade.